Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 25 of 114

  1. CEP-1347 10mg

    Teva Pharma GmbH

    Parkinson Disease

    phase 3 small molecule terminated

    1 trial

  2. CEP-33457

    Teva Pharma GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    2 trials

  3. CETUXIMAB

    Disc Medicine

    oral squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  4. CEXV811A12301

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  5. CF101

    Can-Fite BioPharma

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    2 trials

  6. CF101

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  7. CF101 1 mg

    Can-Fite BioPharma

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  8. CF101 2mg

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  9. CFTY720D2311

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  10. CG0070 Adenovirus Vector

    CG Oncology

    Transitional Cell Carcinoma

    phase 3 mab terminated

    1 trial

  11. CGT9486 plus sunitinib

    Cogent Biosciences

    Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  12. CHF 5993 100/6/12.5 µg

    Chiesi Farmaceutici S.p.A.

    COPD (Chronic Obstructive Pulmonary Disease)

    phase 3 small molecule completed

    1 trial

  13. CHIKV VLP vaccine

    Bavarian Nordic A/S

    Chikungunya Virus

    phase 3 mab active

    2 trials

  14. CHRD 2419

    Novo Nordisk A/S

    Cardiorespiratory arrest at birth in full-term newborns

    phase 3 small molecule active

    1 trial

  15. CHS-0214

    Coherus Oncology

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  16. CHS-1420

    Coherus Oncology

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  17. CI-581a

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 3 small molecule on hold

    1 trial

  18. CINRYZE 500

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 mab completed

    1 trial

  19. CINRYZE 500 U

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  20. CISPLATIN

    Ningbo Cancer Hospital

    Ovarian epithelial cancer : intraperitoneal resectable relapse

    phase 3 small molecule active

    1 trial

  21. CISPLATIN, CARBOPLATIN

    Cardiff Oncology

    Human papillomavirus (HPV)-positive oropharyngeal cancer

    phase 3 small molecule active

    1 trial

  22. CJDQ443B12301

    Novartis Pharmaceuticals

    Advanced non-small cell lung cancer harboring the KRAS G12C mutation

    phase 3 small molecule active

    1 trial

  23. CKD-495 75mg

    Hong Kong Baptist University

    Gastritis

    phase 3 small molecule completed

    1 trial

  24. CKD-501 0.5mg

    Hong Kong Baptist University

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  25. CKJX839A12309

    Novartis Pharmaceuticals

    Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.

    phase 3 small molecule active

    1 trial

  26. CKJX839B12302

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  27. CKJX839C12303

    Novartis Pharmaceuticals

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  28. CKJX839C12304

    Novartis Pharmaceuticals

    homozygous familial hypercholesterolemia

    phase 3 small molecule active

    1 trial

  29. CKJX839D12303

    Novartis Pharmaceuticals

    Non-obstructive Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  30. CL3-95005-006

    The George Institute

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  31. CL3-95031-007

    The George Institute

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  32. CLEE011O12001

    Novartis Pharmaceuticals

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  33. CLEE011O12301C

    Novartis Pharmaceuticals

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  34. CLI-05993AA3-06

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  35. CLI-05993AA5-06

    Chiesi Farmaceutici S.p.A

    Uncontrolled Asthma

    phase 3 small molecule active

    1 trial

  36. CLI-06001AA1-04

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis

    phase 3 small molecule active

    1 trial

  37. CLI-06001AA1-05

    Chiesi Farmaceutici S.p.A

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  38. CLI-06657AA1-01

    Chiesi Farmaceutici S.p.A

    Fabry's disease

    phase 3 other active

    1 trial

  39. CLI-06657AA1-03

    Chiesi Farmaceutici S.p.A

    Fabry disease (α-galactosidase A deficiency)

    phase 3 other active

    1 trial

  40. CLIN-10200-458

    Ipsen

    Treatment of moderate to severe glabellar lines

    phase 3 small molecule active

    1 trial

  41. CLIN-52120-463

    Ipsen

    Chronic migraine

    phase 3 small molecule active

    1 trial

  42. CLIN-52120-464

    Ipsen

    Episodic Migraine

    phase 3 small molecule active

    1 trial

  43. CLIN2001UCM301

    STEBA Biotech S.A

    Low Grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  44. CLNP023A2301

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 3 small molecule active

    1 trial

  45. CLNP023B12301

    Novartis Pharmaceuticals

    complement 3 glomerulopathy

    phase 3 small molecule active

    1 trial

  46. CLNP023Q12301

    Novartis Pharmaceuticals

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  47. CLOBOF3-17IA03

    Laboratorios Tillomed Spain S.L.U

    Inflammation and pain associated with ocular surgery

    phase 3 small molecule active

    1 trial

  48. CLOU064A2303B

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.